Etiology and Treatment of Coronary Arterial Thrombosis: Basic Science and New Clinical Approaches
	University of North Carolina at Chapel Hill , Chapel Hill, NC, USA 05/13/00-05/15/00
	Saturday, May 13, Registration and reception, 7 – 9 p.m. Sunday, May 14, Continental breakfast and late registration, 7:15 a.m.; Welcome, 8 a.m. Session I: The Basic Science of Coronary Arterial Thrombosis Timothy C. Nichols, M.D., UNC-Chapel Hill, and Alice Ma, M.D., UNC-Chapel Hill Are Mice a Model? Stephen M. Schwartz, M.D., Ph.D., Department of Pathology, U.Washington, Seattle, WA Unstable Plaque, Peter Libby, M.D., Brigham and Womens Hospital, Boston, MA Regional Hemostasis Robert D. Rosenberg, M.D., Ph.D., MIT, Cambridge, MA, and Harvard Med Schl, Boston, MA TF and Arterial Clotting, Mark B. Taubman, M.D., Mt Sinai School of Medicine, NY, NY Role of HDL in Atherosclerosis Alan M. Fogelman, M.D., UCLA School of Medicine, Los Angeles, CA Leukocyte Interactions with Platelets and Endothelium Rodger P. McEver, M.D., U. Oklahoma Health Sciences Center, Oklahoma City, OK Role of Platelet Glycoprotein IIb/IIIa Receptor in Arterial Thrombosis Susan Smyth, M.D., Cardiovascular Institute, Mt. Sinai School of Medicine, New York, NY Buffet lunch, 12:15-1:45 p.m. Session II: Risk Factors Stephan Moll, M.D., UNC-Chapel Hill, and Sidney C. Smith, Jr., M.D., UNC-Chapel Hill Atherosclerosis in Children, Youth, and Young Adults: Natural History and Risk Factors Jack P. Strong, M.D., School of Medicine in New Orleans, New Orleans, LA Hypercoagulability Workup Stephan Moll, M.D., Department of Hematology/Oncology, UNC-Chapel Hill Homocysteine Susan C. Guba, M.D., U. Arkansas for Medical Sciences & McClellan VAH, Little Rock, AR SNPs in Thrombotic Cardiovascular Disease George Q. Daley, M.D., Ph.D., Harvard Medical School, Boston, MA Platelet Risk Factors, Andrew I. Schafer, Baylor College of Medicine, Houston, TX Pig pickin’, lawn of Carolina Inn, 6:30 p.m. Monday, May 15, Continental breakfast, 7:15 a.m. Session III: Revascularization/Vasculogenesis David C. Clemmons, M.D., UNC-Chapel Hill, and Gilbert C. White II, M.D., UNC-Chapel Hill Therapeutic Angiogenesis: Basic Principles Stephen E. Epstein, M.D., Cardiovascular Research Foundation, Washington, DC Molecular Mechanisms Responsible for Angiogenesis: VEGF, HIF and PGF Peter Carmeliet, M.D., Ph.D., University of Leuven, Leuven, Belgium bFGF Protein: Preliminary Clinical Results in Coronary and Peripheral Vascular Disease Daisy F. Lazarous, M.D, Johns Hopkins Medical Institutions, Baltimore, MD Clinical Trials of VEGF, Gene Transfer in Patients with Peripheral and Coronary Vascular Disease, Speaker TBA Enabling Technologies for Intra-Myocardial Angiogenesis J. Anthony Ware, M.D., Albert Einstein College of Medicine, Bronx, NY Anti-Angiogenesis to Promote Regression of Athersclerosis Karen S. Moulton, M.D., Childrens Hospital, Boston, MA Buffet lunch, 11:30 a.m. – 1 p.m. Session IV: Therapeutics — Current and Developing Strategies Harold R. Roberts, M.D., UNC-CH, and Guy de Gent, M.D., UNC-CH Current Therapy Questions, Robert M. Califf, M.D., Duke University, Durham, NC IIb/IIIa Inhibitors, Robert Harrington, M.D., Duke University, Durham, NC Heparin, LMH and Hirudin in Coronary Syndromes Lars Wallentin, M.D., Ph.D., Uppsala University Hospital, Uppsala, Sweden New Agents: Anti IX a Michael Blackburn, Ph.D., SmithKline Beecham, King of Prussia PA New Agents: Anti VIIa, Mirella Ezban, Ph.D., Novo Nordisk A/S, Målov, Denmark Genetic Variation in Integrin Alpha-2 Beta-1 Density and Its Impact on Platelet Adhesion and Thrombus Formation, Thomas J. Kunicki, Ph.D., Scripps Research Institute, La Jolla, CA Directed Inhibitors, Frank C. Church, Ph.D., UNC-Chapel Hill Closing remarks and adjournment, 4:10 p.m.
	Organized by:	UNC-CH Center for Thrombosis and Hemostasis
	Deadline for Abstracts:	not applicable
	Registration:	$325 (U.S.) Registration; seating limited
	Email for Requests and Registration:	catmeet@med.unc.edu
	Posted by: Jaime Welch-Donahue   Host: 152.19.60.127 date: January 12, 2000 20:11:41 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.